buy final cut pro 4.1 buy photoshop cs4 student edition best buy adobe photoshop cs3 microsoft windows 7 professional oem download price of microsoft office 2010 home and student price of adobe contribute buy realflow windows 7 professional oem pricing buy microsoft office 2010 student and home discount windows 7 student full version buy ms office 2007 small business oem windows 7 ultimate price us buy windows 7 family pack in canada buy ms money download buy audition 3 upgrade
solidworks discount cost of ms office 2013 professional plus buy adobe photoshop cs3 windows buy word 2000 online best price office 2007 pro cheap rosetta stone english software cheap roxio creator 2011 cost of visio software buying encarta encyclopedia buy windows xp 64 bit sp2 buy cs4 mac serial paint shop pro cost buy windows 7 in bulk windows 2008 datacenter edition pricing windows 7 ultimate license price

Tag Archive | "cetuximab"

Epidermal Growth Factor Receptor and the Changing Face of Oropharyngeal Cancer

Friday, March 9, 2012

0 Comments

Source: Journal of Clinical Oncology To the Editor: In their article, Chaturvedi et al1 document the rise in human papillomavirus (HPV) –associated cancers as a proportion of squamous cell carcinomas of the oropharynx over the last 25 years. The contemporary figures are mirrored by two recent British studies2,3 demonstrating that the majority of oropharyngeal cancers […]

Continue reading...

Use of carbon nanoparticles paves way to customized cancer therapy

Sunday, February 19, 2012

0 Comments

Source: www.azonano.com Author: Cameron Chai A research study by Jeffrey Myers from the University of Texas MD Anderson Cancer Center and James Tour from the Rice University has reported that a combination of carbon nanoparticles and existing drugs has the capability to improve head-and-neck cancer treatment, particularly when coupled with radiation therapy.   The novel […]

Continue reading...

Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E–Mediated Anaphylaxis

Thursday, January 19, 2012

0 Comments

Source: Journal of Clinical Oncology To the Editor: In Journal of Clinical Oncology, Tronconi et al1 report a fatal hypersensitivity reaction to cetuximab in a 63-year-old patient with metastatic colon cancer and outlined a 0.1% incidence of death in the literature. We greatly acknowledge the authors’ desire to communicate the risk of fatal anaphylactic reaction […]

Continue reading...

Third Head and Neck Indication for Erbitux

Thursday, January 5, 2012

0 Comments

Source: The ASCO Post, January 1, 2012, Volume 3, Issue 1, Matthew Stenger   In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.Cetuximab (Erbitux) was recently approved by the FDA for use in combination with platinum-based therapy […]

Continue reading...

FDA Approves Cetuximab for Late-Stage Head and Neck Cancer

Wednesday, November 9, 2011

0 Comments

Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with […]

Continue reading...

US FDA approval for expanded use of Erbitux

Wednesday, November 9, 2011

0 Comments

Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line […]

Continue reading...

FDA Approves Cetuximab for Metastatic Head and Neck Cancer

Tuesday, November 8, 2011

0 Comments

Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is […]

Continue reading...

New Therapies and Prognostic Techniques Highlighted in Head and Neck Cancer

Tuesday, October 18, 2011

0 Comments

The Asco Post D. Neil Hayes, MD, MPH, of the University of North Carolina at Chapel Hill, described efforts to position the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) in head and neck cancer treatment. Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed […]

Continue reading...

Researchers find potential new therapeutic strategy for head and neck cancer

Friday, September 23, 2011

0 Comments

Source: www.uab.edu Author: Beena Thannickal Shih-Hsin (Eddy) Yang, M.D., Ph.D., an assistant professor in the UAB Department of Radiation Oncology and associate scientist in the experimental therapeutics program at the UAB Comprehensive Cancer Center, found a way to prevent head and neck cancer cells from repairing damage to DNA as they grow. The findings, published […]

Continue reading...

Cancer drug resistance strategy uncovered

Friday, September 9, 2011

0 Comments

Source: Cancer Research UK Author: Staff   Friday 9 September 2011- US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying […]

Continue reading...